L04AK02 · Antineoplastic and immunomodulating agents
Teriflunomide Viatris (previously Teriflunomide Mylan)
Indications
Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established).
Composition
- Active substance
- teriflunomide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Teriflunomide Viatris (previously Teriflunomide Mylan)
- Active substance
- teriflunomide
- ATC code
- L04AK02
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting